Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diltiazem + olmesartan medoxomil
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two separate medications used together for hypertension treatment. Diltiazem is a calcium channel blocker that inhibits calcium influx across cell membranes in cardiac and vascular smooth muscle. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. When used together, these medications may have complementary effects on blood pressure through different mechanisms, but also potential for additive effects that require monitoring.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on diltiazem + olmesartan medoxomil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diltiazem + olmesartan medoxomil.